Overview
Lymphomatoid papulosis (LYP) is characterized by recurrent crops of papulonodular skin lesions with variable histological subtypes, often benign in nature despite malignant-appearing histology 124.Diagnosis
Recurrent papulonodular skin lesions 1.
Histological examination revealing diverse growth patterns and immunophenotypes, including follicular involvement in rare variants 24.
Distinct histological types (A-E) and additional subtypes based on genetic features 1.
Biopsy essential for diagnosis, showing atypical lymphoid cells 3.Management
First-line treatment: Methotrexate (5-25 mg orally weekly) shows good clinical efficacy and potential superiority over PUVA 3.
Adjunctive treatments: No specific adjunctive treatments highlighted in the abstracts 3.Special Populations
No specific guidance provided for pregnancy, pediatrics, elderly, or comorbidities in the given abstracts [].Key Recommendations
Use descriptive histological terms rather than complex alphabetic classifications for clarity in diagnosis (Evidence: Expert opinion) 1.
Consider methotrexate as a first-line treatment option for managing lymphomatoid papulosis due to its efficacy and potential superiority over other therapies (Evidence: Weak) 3.
Biopsy is crucial for confirming diagnosis and identifying specific histological subtypes, especially in suspected follicular variants (Evidence: Moderate) 24.References
1 Kempf W, Mitteldorf C, Karai LJ, Robson A. Lymphomatoid papulosis - making sense of the alphabet soup: a proposal to simplify terminology. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2017. link
2 Sexton FM, Maize JC. Follicular lymphomatoid papulosis. The American Journal of dermatopathology 1986. link
3 Lange Wantzin G, Thomsen K. Methotrexate in lymphomatoid papulosis. The British journal of dermatology 1984. link
4 Pierard GE, Ackerman AB, Lapiere CM. Follicular lymphomatoid papulosis. The American Journal of dermatopathology 1980. link